Deletion of CD98 heavy chain in T cells results in cardiac allograft acceptance by increasing regulatory T cells

Transplantation

Volumn 93, Issue 11, 2012, Pages 1116-1124

  Liu, Zhong ^a,b   Hou, Jiangang ^a   Chen, Jiajie ^a   Tsumura, Hideki ^a   Ito, Morihiro ^c   Ito, Yasuhiko ^c   Hu, Xiang ^b   Li, Xiao Kang ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c CHUBU UNIVERSITY   (Japan)

Author keywords

Allograft; Cardiac transplantation; CD98hc; Foxp3; Regulatory T cell; Tolerance

Indexed keywords

CD4 ANTIGEN; CD98 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 26 24; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; S6 KINASE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; GENE EXPRESSION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; HLA MATCHING; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE REACTION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD98 HEAVY CHAIN; BASE SEQUENCE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; ISOANTIGENS; KAPLAN-MEIER ESTIMATE; LEUKOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; SEQUENCE DELETION; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84862283748     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824fd7cd     Document Type: Article

References (32)

1. Bertran J, Magagnin S, Werner A, et al. Stimulation of system y(+)-like amino acid transport by the heavy chain of human 4F2 surface antigen in Xenopus laevis oocytes. Proc Natl Acad Sci USA 1992; 89(12): 5606.
2. Torrents D, Estevez R, Pineda M, et al. Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance. J Biol Chem 1998; 273(49): 32437.
3. Fenczik CA, Sethi T, Ramos JW, et al. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997; 390(6655): 81.
4. Feral CC, Nishiya N, Fenczik CA, et al. CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci USA 2005; 102(2): 355.
5. Zent R, Fenczik CA, Calderwood DA, et al. Class-and splice variantYspecific association of CD98 with integrin beta cytoplasmic domains. J Biol Chem 2000; 275(7): 5059.
6. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998; 10(3): 330.
7. Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 2007; 19(3): 162.
8. Prager GW, Feral CC, Kim C, et al. CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling. J Biol Chem 2007; 282(33): 24477.
9. Cai S, Bulus N, Fonseca-Siesser PM, et al. CD98 modulates integrin beta1 function in polarized epithelial cells. J Cell Sci 2005; 118(pt 5): 889.
10. Kehrl JH, Fauci AS. Identification, purification, and characterization of antigen-activated and antigen-specific human B lymphocytes. Trans Assoc Am Physicians 1983; 96: 182.
11. Tsumura H, Suzuki N, Saito H, et al. The targeted disruption of the CD98 gene results in embryonic lethality. Biochem Biophys Res Commun 2003; 308(4): 847.
12. Lee PP, Fitzpatrick DR, Beard C, et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 2001; 15(5): 763.
13. Tsumura H, Kawano M, Tajima M, et al. Isolation and characterization of monoclonal antibodies directed against murine FRP-1/CD98/4F2 heavy chain: murine FRP-1 is an alloantigen and amino acid change at 129 (PGY9R) is related to the alloantigenicity. Immunol Cell Biol 1999; 77(1): 19.
14. Cantor J, Browne CD, Ruppert R, et al. CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat Immunol 2009; 10(4): 412.
15. Komada H, Imai A, Hattori E, et al. Possible activation of murine T lymphocyte through CD98 is independent of interleukin 2/interleukin 2 receptor system. Biomed Res 2006; 27(2): 61.
16. Diaz LA Jr, Friedman AW, He X, et al. Monocyte-dependent regulation of T lymphocyte activation through CD98. Int Immunol 1997; 9(9): 1221.
17. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996; 84(3): 359.
18. Deves R, Chavez P, Boyd CA. Identification of a new transport system (y+L) in human erythrocytes that recognizes lysine and leucine with high affinity. J Physiol 1992; 454: 491.
19. Mulligan MS, McDuffie JE, Shanley TP, et al. Role of RANTES in experimental cardiac allograft rejection. ExpMol Pathol 2000; 69(3): 167.
20. Russell ME, Adams DH, Wyner LR, et al. Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci USA 1993; 90(13): 6086.
21. Fleury S, Li J, Simeoni E, et al. Gene transfer of RANTES and MCP-1 chemokine antagonists prolongs cardiac allograft survival. Gene Ther 2006; 13(14): 1104.
22. Kitazawa Y, Fujino M, Wang Q, et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007; 83(6): 774.
23. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531.
24. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14(1): 88.
25. Tsang JY, Tanriver Y, Jiang S, et al. Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression. Transpl Immunol 2009; 21(4): 203.
26. Zhang Q, Iwami D, Aramaki O, et al. Prolonged survival of fully mismatched cardiac allografts and generation of regulatory cells by Sairei-to, a Japanese herbal medicine. Transplantation 2009; 87(12): 1787.
27. Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005; 201(7): 1037.
28. Kohm AP, McMahon JS, Podojil JR, et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 2006; 176(6): 3301.
29. Powell JD. The induction and maintenance of T cell anergy. Clin Immunol 2006; 120(3): 239.
30. Trinh XB, Tjalma WA, Vermeulen PB, et al. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009; 100(6): 971.
31. Hayashi T, Morishita E, Ohtake H, et al. Expression of annexin II in human atherosclerotic abdominal aortic aneurysms. Thromb Res 2008; 123(2): 274.
32. Hatanaka Y, Hashizume K, Nitta K, et al. Cytometrical image analysis for immunohistochemical hormone receptor status in breast carcinomas. Pathol Int 2003; 53(10): 693.